

REMARKS

Summary of Office Action

Claims 16, 17, 19, 20, 22, 24-28 and 30 are pending. Claim 26 is objected to under 37 C.F.R. 1.75(c). Claims 27, 28, and 30 are rejected under 35 U.S.C. § 112. Claims 16, 17, 19, 20, 22, 24, and 25 are allowable.

Objection under 37 C.F.R. 1.75(c)

The Examiner's objection to claim 26, for failing to limit the subject matter of independent claim 22, from which it depends, is overcome by the cancellation of the claim.

Rejection under 35 U.S.C. § 112, first paragraph

Claims 27, 28, and 30, which are directed to methods of compound screening that require a rab5 transgenic mouse, are rejected as lacking enablement.

While applicants do not agree with the present rejection and reserve the right to pursue all canceled subject matter future, related applications, in order to expedite prosecution, applicants cancel rejected claims 27, 28, and 30.

CONCLUSION

The Examiner has indicated that claims 16, 17, 19, 20, 22, 24, and 25 are in condition for allowance, and such action is respectfully requested. If the Office does not concur, a telephonic interview with the undersigned is hereby requested.


Enclosed is a Petition to extend the period for replying to the final Office Action for one month, to and including August 6, 2004, and a check in payment of the required extension fee.

If there are any additional charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

August 5, 2004



Kristina Bieker-Brady, Ph.D., P.C.
Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045